Direkt zum Inhalt
Merck
  • Oral adherence monitoring using a breath test to supplement highly active antiretroviral therapy.

Oral adherence monitoring using a breath test to supplement highly active antiretroviral therapy.

AIDS and behavior (2012-09-25)
Timothy E Morey, Matthew Booth, Scott Wasdo, Judith Wishin, Brian Quinn, Daniel Gonzalez, Hartmut Derendorf, Susan P McGorray, Jane Simoni, Richard J Melker, Donn M Dennis
ZUSAMMENFASSUNG

A breath-based adherence system to document ingestion of oral medications (e.g., HAART) was investigated. Specifically, the food additive 2-butanol, which can be easily packaged with a drug, is converted via alcohol dehydrogenase to the volatile metabolite 2-butanone that rapidly appears in breath, indicating adherence. In healthy adults using a portable sensor and GC-MS, the following experiments were performed: yield of 2-butanone in breath following ingestion of 2-butanol, adherence system accuracy, and potential interference of the adherence system by food or misplacement of 2-butanol on the tongue. During feasibility testing, every subject exhaled 2-butanone with 6.6 ± 1.5 min to peak concentrations of 548 ± 235 ppb following ingestion of 2-butanol (40 mg). ROC areas at 5 and 10 min were 0.95 (0.86-1.00) and 1.00 (1.00-1.00). Food did not interfere. Tongue application resulted in large concentrations of 2-butanol, but not 2-butanone. A breath test to provide definitive evidence of oral medication adherence appears technically feasible.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
2-Butanol, ReagentPlus®, ≥99%
Sigma-Aldrich
Aluminium-tri-sec-butoxid, 97%
Sigma-Aldrich
2-Butanol, anhydrous, 99.5%
Sigma-Aldrich
(S)-(+)-2-Butanol, 99%
Supelco
2-Butanol, analytical standard